Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy
- Written by PR Newswire Asia - Asian Spectator
![Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy](https://www.prnasia.com/6_actinogen_colour_logo_0.jpg "logo"){kind=logo} |
The study confirms that Xanamem is a brain-penetrant inhibitor of the tissue cortisol synthesis enzyme, 11β-HSD1, with high levels of target occupancy at doses as low as 5 mg
SYDNEY, Jan. 24, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that its human Positron Emission Tomography (PET) study, confirming high levels...
